Effects of Tenofovir on the Single-Dose Pharmacokinetics of Intravenous Morinidazole in Healthy Chinese Subjects

Guolan Wu; Wenling Tang; Duo Lv; Lihua Wu; Huili Zhou; Xi Yang; Yunliang Zheng; You Zhai; Jianzhong Shentu

doi:10.1128/AAC.02067-19

Effects of Tenofovir on the Single-Dose Pharmacokinetics of Intravenous Morinidazole in Healthy Chinese Subjects

Antimicrob Agents Chemother. 2020 Apr 21;64(5):e02067-19. doi: 10.1128/AAC.02067-19. Print 2020 Apr 21.

Authors

Guolan Wu^{1

2}, Wenling Tang³, Duo Lv^{1

2}, Lihua Wu^{1

2}, Huili Zhou^{1

2}, Xi Yang⁴, Yunliang Zheng^{1

2}, You Zhai^{1

2}, Jianzhong Shentu^{5

2}

Affiliations

¹ Research Center of Clinical Pharmacy, State Key Laboratory for Diagnosis and Treatment of Infectious Disease, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
² Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
³ College of Medicine, Zhejiang University, Hangzhou, China.
⁴ Department of Pharmacy, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
⁵ Research Center of Clinical Pharmacy, State Key Laboratory for Diagnosis and Treatment of Infectious Disease, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China stjz@zju.edu.cn.

Abstract

The effects of multiple-dose administration of tenofovir disoproxil fumarate (TDF) on the pharmacokinetics of morinidazole (MOR) were compared in healthy subjects. MOR exposure was similar, with an area under the curve from 0 h to infinity (AUC_0-∞) treatment ratio for MOR+TDF/MOR of 1.01 (90% confidence interval, 0.97 to 1.06). No relevant differences were observed regarding plasma exposure of metabolites. Renal clearances of MOR and its metabolites were not affected by TDF. No unexpected safety or tolerability issues were observed.

Keywords: clinical pharmacokinetics; drug-drug interaction; morinidazole; organic anion transporter; tenofovir.

Publication types

Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Antiviral Agents / pharmacokinetics*
Antiviral Agents / pharmacology*
China
Drug Interactions*
Healthy Volunteers
Humans
Nitroimidazoles / pharmacokinetics*
Tenofovir / pharmacology*

Substances

Antiviral Agents
Nitroimidazoles
Tenofovir
morinidazole